Following the Data—Wherever It Leads
Ben has often said that one of the most important responsibilities of a scientist is to “follow the data”. That sounds simple, but sometimes following the data means arriving at a different conclusion than the one you held before.
That is exactly what has been happening with Ben’s thinking about GLP-1-based medications.
As a Reminder... You can use the “speedometer” icon at the bottom of the video to watch at various speeds.
The Study Dr. Bikman Refers To
Ben refers to a newly released study led by himself and the team at Summit Family Health & Metabolic Clinic, including Insulin IQ’s Coaching Director, Carlie Wendel, examining the combination of a whole-food ketogenic diet, personalized coaching, and low-dose semaglutide (Ozempic/Wegovy). In this small six-month case series, participants lost an average of nearly 48 pounds, with about 92% of the weight loss coming from body fat rather than muscle, while also improving several key markers of metabolic health. Although the results are promising, Ben emphasizes that larger, randomized clinical trials are needed to confirm these preliminary findings.
Ben said, “The paper published this week looked at the use of low dose GLP-1 drugs when combined with coaching, and low-carb, ketogenic diets. The results were just phenomenal. People were able to stay at very low doses and have substantially greater fat loss than when it was just the drug alone.”
You can download the full study by clicking the image below:
Science is not static.
New studies are published. Better data become available. Earlier findings are reexamined. And sometimes a concern that once seemed compelling looks different as our understanding becomes more complete.
For Dr. Bikman, following the data means not defending something he said—even fairly recently—simply because he said it. It means continuing to ask what the evidence shows now—even when the answer leads somewhere he did not initially expect to go.
Today, Ben says plainly, “I think there’s absolutely a place for these drugs.”
But understanding what he means by that is critical.
Additional Recent Studies, Lectures and Podcast Reviews
Review #75: Do GLP-1 Drugs Destroy Muscle? The Truth May Be Different (May 4, 2026)
Dr. Bikman reviews a 2026 study challenging concerns that GLP-1 drugs cause significant muscle loss, finding that they primarily reduce fat while largely preserving muscle strength, endurance, and function.
Review #81: GLP-1 Medications and the Psychology of Lasting Change (Jun 15, 2026)
Dr. Bikman reviews a 2026 paper suggesting that GLP-1 medications can create a temporary window of reduced cravings that should be used to build lasting behavioral and lifestyle habits that can persist after the medication is discontinued.
Review #84: The Lowest Effective Dose of GLP-1 Therapy (Jul 8, 2026)
Dr. Bikman reviews a 2026 study suggesting that individualized, lower-dose semaglutide may produce substantial weight loss while improving tolerability and reducing the need for automatic escalation to the highest approved dose.
Why Tirzepatide Works Better Than GLP-1 Alone (May 18, 2026)
Tirzepatide activates both GLP-1 and GIP receptors, producing weight loss primarily through appetite suppression, slower gastric emptying, reduced cravings, and improved insulin sensitivity—not by forcing the pancreas to make more insulin. Dr. Bikman argues that its best use may be as a temporary tool to help people regain control of food choices and lower the insulin-driving habits that caused metabolic dysfunction.
Why Retatrutide May Outperform GLP-1 Drugs (May 25, 2026)
Retatrutide activates GLP-1, GIP, and glucagon receptors, combining appetite suppression with increased energy expenditure and powerful liver fat reduction. Dr. Bikman argues that its best use is not as a permanent shortcut, but as a tool to help people regain control over food habits and eventually reduce reliance on medication.
The Drugs Aren’t the Only Issue. The Doses Matter.
This is an important distinction because Ben has not simply embraced the conventional way these medications are often prescribed.
In many treatment protocols, patients begin at a standardized dose and are then moved progressively toward larger doses. Ben has consistently questioned the idea that more medication is automatically better.
His preference is much more cautious: use the lowest effective dose, increase only when there is a good reason to do so, and be patient. In many cases, that can mean what is commonly called “microdosing.”
The goal should not be to suppress appetite so dramatically that a person can barely eat. It should be to use only as much medication as necessary to provide metabolic benefit while still allowing adequate nutrition—especially protein—and preserving muscle.
A Medication Is Not a Metabolic-Health Strategy
This may be the most important thing that has not changed in Ben’s thinking.
Insulin resistance still matters. Food quality still matters. Adequate protein still matters. Resistance training and preserving muscle still matter. Sleep, activity, and the behaviors that determine long-term metabolic health still matter.
A GLP-1-based medication can potentially help create an opportunity for someone to make those changes. But the medication should not become a substitute for them.
That is also why Ben does not believe the objective should automatically be to keep increasing the dose—or necessarily to remain on the medication forever. For some people, a carefully used medication may help them regain enough metabolic control to make changes that eventually allow the dose to be reduced or, when appropriate, discontinued under medical supervision.
What About Ben’s Relationship With Metabody?
There is another question we think deserves a direct answer.
Ben is now the scientific advisory board chair at Metabody.ai, a company working in metabolic health that includes access to GLP-1-based medications. Knowing that, it is perfectly reasonable for someone who remembers Ben’s earlier skepticism to wonder whether a financial relationship caused his position to change.
The timeline matters.
Ben’s thinking about these medications had already begun changing as he studied the emerging research and reconsidered the physiology. His involvement with Metabody came later. The business relationship did not create the change in his scientific thinking.
In fact, Ben’s involvement gives him an opportunity to advocate for something he believes is badly needed in this space: a more metabolically intelligent way of using these medications—one that emphasizes appropriate dosing, adequate nutrition, preservation of muscle, insulin sensitivity, and long-term metabolic health rather than simply maximizing weight loss.
So, Has Ben Changed His Mind?
Yes. The evidence changed his view of where GLP-1-based medications may have a legitimate role.
But he has not changed his mind about the larger principles that have defined his work for years.
The goal is still better metabolic health—not simply a lower number on the scale. Insulin resistance still matters. Muscle still matters. Nutrition still matters. And medication, when it is used, should support those goals rather than replace them.
That is the part of Ben’s position that hasn’t changed at all.
